Skip Navigation

Advertise|Press|Contact|FAQ|CWConnect

Bookmark/Print/Share

Home » Clinical Trials » Lymphoma, B-Cell

Clinical Trial Details

Overview

Research Study Summary

A Phase 1/Phase 2 clinical study for patients with Diffuse Large B Cell Lymphoma

Research Study Title

Phase I/II Trial of Azacytidine + R-CHOP in Diffuse Large B-Cell Lymphoma

Purpose

This is a phase I/II open label, multi-center study of azacytidine in combination with standard RCHOP therapy in patients with DLBCL. Patients will be treated with azacytidine at escalating doses on days 1-5, followed by standard dose rituximab plus CHOP chemotherapy on day 8, every 21 days. Patients will be treated for a total 6 cycles. The phase II portion will then evaluate efficacy of the combination at the established MTD.

To Learn more
Phase

1/2

Gender

Both Male and Female

Age

18 and up

Overall Status

Recruiting

Lead Sponsor

Weill Medical College of Cornell University

Duration

36 Months

Facility Type

N/A

Eligibility

Both Male and Female ages 18 Years and up

Inclusion Criteria:

  • Patients must have histologically confirmed DLBCL with characteristic immunophenotypic profiles. Tumor tissue must be confirmed to express the CD20 antigen by flow cytometry or immunohistochemistry.

  • Patients must have at least one site of measurable disease, 1.5 cm in diameter or greater.

  • Patient has not had any previous treatment.

  • Stage II (not appropriate for abbreviated chemoimmunotherapy and radiotherapy), III or IV disease

  • Able to adhere to the study visit schedule and other protocol requirements.

  • Patients must have laboratory test results within these ranges:

  • Absolute neutrophil count > = 1500/mm³

  • Platelet count > = 75,000/mm³

  • Serum creatinine < = 1.5X upper limit of normal (ULN)

  • Total bilirubin < = 1.5X ULN. Higher levels are acceptable if these can be attributed to active hemolysis or ineffective erythropoiesis.

  • AST (SGOT) and ALT (SGPT) < = 2 x ULN

  • Disease free of prior malignancies for > = 5 years with exception of currently treated basal cell, squamous cell carcinoma of the skin, or carcinoma "in situ" of the cervix or breast.

  • Women of childbearing potential must have a negative serum pregnancy test prior to azacitidine treatment.

  • Women of childbearing potential should be advised to avoid becoming pregnant and men should be advised to not father a child while receiving treatment with azacitidine. The effects of azacytidine on the developing human fetus at the recommended therapeutic dose are unknown. For this reason, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.

  • Age > 18 years.

  • Ability to understand and the willingness to sign a written informed consent document.

  • ECOG performance status of 0-2

Exclusion Criteria:

  • Patients must not have any serious medical condition, laboratory abnormality,or psychiatric illness that would prevent the subject from signing the informed consent form.

  • Patients must not have any condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study.

  • Use of any other experimental drug or therapy within 28 days of baseline.

  • Concurrent use of other anti-cancer agents or treatments.

  • Known positive for HIV or infectious hepatitis B.

  • Known central nervous system involvement by lymphoma.

  • Known or suspected hypersensitivity to azacitidine or mannitol.

  • Patients must not have advanced malignant hepatic tumors.

  • Pregnant and lactating women are excluded from the study because the risks to an unborn fetus or potential risks in nursing infants are unknown.

Site Locations (1)

Country State City Zip Facility and Contact
United States New York New York 10065 Weill Cornell Medical College
Rebecca Elstrom, MD
212-746-2063
ree2001@med.cornell.edu

Rebecca Elstrom, MD
Principal Investigator

Contact

Rebecca Elstrom, MD
212-746-2063

If you would like to learn more about participating in this research study, please email the trial contact using the form below.

Name:
Address:
City:
State:
Zip/Postal Code:
Country:
Phone:
Email:  
Message:
 
Please leave this field empty.

NCT ID: NCT01004991

Date Last Changed: March 8, 2011

DISCLAIMER: This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials. Some study summaries have been edited for clarity purposes to make them easier to understand. View more study details here.